GPT and metabolic dysfunction-associated steatohepatitis: Rifaximin, an antibiotic that is not absorbed in the intestines, has demonstrated significant reductions in AST, ALT, low-density lipoprotein (LDL), and BMI among patients with NASH [201,202].